All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

ADCs Are Poised to Transform the Metastatic TNBC Treatment Arsenal

April 18th 2025

Nerea Lopetegui-Lia, MD, discusses ongoing trials investigating ADCs that are shaking up the metastatic triple-negative breast cancer setting.

Cyclin E1 Positivity May Enhance Patient Selection for Azenosertib in Platinum-Resistant Ovarian Cancer

April 18th 2025

Fiona Simpkins, MD, discusses the use of cyclin E1 positivity as a biomarker of azenosertib response in platinum-resistant ovarian cancer.

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma

April 18th 2025

María-Victoria Mateos, MD, PhD, discusses data from the long-term update of CARTITUDE-4 she presented during the 51st Annual EBMT Meeting.

Tarlatamab and Durvalumab Enhance the SCLC Immunotherapy Paradigm

April 18th 2025

Isabel Preeshagul, DO, MBS, discusses frontline treatment selection for patients with SCLC and significant FDA approvals in this disease.

Investigational and Established Biomarkers Guide Ongoing CRPC Therapy Developments

April 18th 2025

Evan Y. Yu, MD, discusses future directions for biomarker research and targeted therapy development for patients with castration-resistant prostate cancer.

New Jersey Patients Receiving First-of-Its-Kind Catheter Based Pancreatic Cancer Treatment

April 18th 2025

Hackensack Meridian Jersey Shore University Medical Center experts have successfully treated their first patients using RenovoRx’s Novel Trans-Arterial Micro-Perfusion therapy platform.

Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer

April 18th 2025

Dostarlimab/chemotherapy was granted an expanded approval by Health Canada to treat patients with primary advanced or first recurrent endometrial cancer.

Global Analysis Shows Significant Variability in Sarcoma Clinical Trial Availability

April 18th 2025

High variability in sarcoma clinical trial funding, location, and phase was identified in a global analysis conducted over the past decade.

LV20.19 CAR T-Cell Therapy Yields 100% ORR and Manageable Toxicity in R/R MCL

April 18th 2025

On-site adaptive manufacturing of LV20.19 resulted in a high complete response rate and favorable tolerability in relapsed/refractory mantle cell lymphoma.

An EBMT Machine Learning Model Aids With Transplant Risk Stratification in Myelofibrosis

April 18th 2025

Juan Carlos Hernández-Boluda, MD, PhD, discusses the development of an EBMT machine learning model for predicting allo-HCT risk in myelofibrosis.

Subtype-Specific Considerations, Surgical Innovation, and Functional Preservation Are Central to HNSCC Management

April 18th 2025

Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.

JAK Inhibitor Safety Is at the Heart of Treatment Selection in Myelofibrosis

April 17th 2025

Jamile M. Shammo, MD, discusses how the differences between the available JAK inhibitors in myelofibrosis guide her treatment considerations.

USC Norris Comprehensive Cancer Center Opens State-of-the-Art Newport Beach Radiation Oncology and Imaging Center

April 17th 2025

USC Norris Comprehensive Cancer Center has opened Keck Medicine of USC – Newport Beach Radiation Oncology and Imaging, a radiation oncology center.

Belantamab Mafodotin–Based Combos Win UK Approval for R/R Myeloma

April 17th 2025

Two belantamab mafodotin–based combinations have been approved in the United Kingdom for relapsed/refractory multiple myeloma.

Bria-IMT Plus Checkpoint Inhibition Yields Potential OS Benefit in Pretreated HR+ Breast Cancer

April 17th 2025

Bria-IMT plus retifanlimab generated a potential overall survival benefit in heavily pretreated, metastatic hormone receptor–positive breast cancer.

Companion Diagnostic Nets European IVDR Certification for Pembrolizumab Eligibility in Gastric/GEJ Adenocarcinoma

April 17th 2025

The PD-L1 IHC 22C3 pharmDx assay has been granted European IVDR certification for identifying pembrolizumab eligibility in gastric/GEJ adenocarcinoma.

Dasatinib Plus CAR T-Cell Therapy Shows Efficacy in Ph+ Acute Lymphoblastic Leukemia

April 17th 2025

Dasatinib plus CAR T cells led to high CMR and LFS rates with a good safety profile in Ph-positive acute lymphoblastic leukemia.

Talazoparib/Enzalutamide Combo, Radioligand Therapy Expand Options in mCRPC

April 17th 2025

Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for advanced metastatic prostate cancer.

Responses With Compassionate Use of MDC-CAR-BCMA001 Support Further Study in R/R Myeloma and AL Amyloidosis

April 17th 2025

Kiavasch Mohammad Nejad Farid, MD, discusses the signs of activity and safety with MDC-CAR-BCMA001 in pretreated patients with AL amyloidosis and myeloma.

Anthracycline-Sparing Strategies Help Refine HER2+ Breast Cancer Management

April 17th 2025

Paolo Tarantino, MD, discusses the growing emphasis on anthracycline-sparing approaches for the treatment of HER2-positive breast cancer.